Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effects of Tiger Milk Mushroom Supplementation on Physical Performance in Physically Active Adults

lauantai 8. elokuuta 2026 päivittänyt: Nexus Wise Sdn Bhd

Effects of Tiger Milk Mushroom (Lignosus Rhinocerus) Supplementation on Physical Performance, Exercise Recovery, and Wellbeing in Physically Active Adults: A Randomized Double-Blind Placebo-Controlled Trial

This study aims to evaluate the effects of Tiger Milk Mushroom (TMM) supplementation on physical performance and overall wellbeing in physically active adults.

Tiger Milk Mushroom (Lignosus rhinocerus) is a medicinal mushroom traditionally used in Southeast Asia for promoting health and vitality. Previous laboratory and clinical studies have suggested that Tiger Milk Mushroom possesses antioxidant, anti-inflammatory, and immunomodulatory properties that may support physical function, exercise recovery, and overall health.

In this randomized, double-blind, placebo-controlled trial, 60 physically active adults aged 18 years and above will be randomly assigned to receive either Tiger Milk Mushroom supplementation or a matching placebo for 12 weeks. Participants in the intervention group will consume one capsule of Tiger Milk Mushroom twice daily, while participants in the placebo group will consume matching placebo capsules following the same schedule. Assessments will be conducted at baseline, week 6, and week 12.

The study will evaluate physical performance through measurements of muscle strength, heart rate, self-paced walking performance, perceived exertion, and aerobic capacity (VO₂max). Blood samples will be collected to assess biomarkers related to cardiovascular endurance, exercise recovery, inflammation, and general health, including cortisol, total iron-binding capacity, creatine kinase, interleukin-2, and interleukin-6. Participants' stress levels and overall wellbeing will also be assessed using validated questionnaires.

The purpose of this study is to determine whether Tiger Milk Mushroom supplementation can support physical performance, exercise capacity, recovery, and overall wellbeing in physically active adults.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Physical performance is an important determinant of overall health, functional capacity, and quality of life. Optimal physical performance depends on multiple physiological factors, including muscular strength, cardiovascular endurance, recovery capacity, and the regulation of inflammation and oxidative stress. During physical exertion, increased metabolic activity leads to the production of reactive oxygen species (ROS) and inflammatory mediators, which may contribute to muscle fatigue, impaired recovery, reduced exercise capacity, and decreased physical performance. Therefore, interventions capable of reducing oxidative stress and inflammation may offer benefits in enhancing physical performance and exercise recovery.

Lignosus rhinocerus, commonly known as Tiger Milk Mushroom (TMM), is a medicinal mushroom belonging to the Polyporaceae family and has been traditionally used in Southeast Asia and China for promoting general health and treating various ailments. The sclerotium of TMM contains numerous bioactive compounds, including polysaccharides, glycoproteins, phenolic compounds, and triterpenoids, which have been reported to possess antioxidant, anti-inflammatory, antimicrobial, immunomodulatory, and neuroprotective properties. Previous in vitro and animal studies have demonstrated that TMM can suppress the production of pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α), and protect cells against oxidative damage. These biological activities suggest a potential role for TMM in improving exercise performance and recovery.

Oxidative stress and exercise-induced inflammation are recognised contributors to muscle fatigue, reduced endurance, and impaired physical performance. Studies have shown that dietary interventions with antioxidant and anti-inflammatory properties may enhance muscle function, improve aerobic capacity, and accelerate post-exercise recovery. Given the documented antioxidant and anti-inflammatory activities of TMM, supplementation with TMM may help attenuate exercise-induced physiological stress, preserve muscle function, and enhance overall physical performance.

Although several studies have investigated the pharmacological properties of TMM and its effects on respiratory health, immunity, and antioxidant status, clinical evidence regarding its efficacy in improving physical performance remains limited. A previous randomized controlled trial reported beneficial effects of TMM supplementation combined with resistance training on muscular strength, aerobic fitness, anaerobic performance, and immune parameters in young adults. However, further studies are required to better understand the effects of TMM supplementation on physical performance, cardiovascular endurance, exercise recovery, inflammatory responses, and perceived wellbeing in healthy individuals.

Therefore, this study aims to evaluate the effects of Tiger Milk Mushroom supplementation on physical performance among healthy adults by assessing muscle strength, cardiovascular endurance, exercise-related inflammatory markers, stress levels, and overall wellbeing.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

65

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Malesia
    • Kuala Lumpur
      • Cheras, Kuala Lumpur, Malesia, 56000
        • UCSI University

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

  • Male or female adults aged 18 years and above
  • Physically active individuals who regularly participate in physical exercise or fitness-related activities
  • Generally healthy based on self-reported medical history
  • Willing and able to comply with all study procedures and scheduled visits
  • Willing to provide written informed consent

Exclusion Criteria:

  • Current cigarette smokers
  • Users of psychoactive substances
  • Individuals consuming more than 600 mL of caffeinated beverages per day
  • Diagnosis of chronic metabolic diseases, including but not limited to type 2 diabetes mellitus or cardiovascular disease
  • Diagnosis of autoimmune disease
  • Pregnant or lactating women
  • Known allergy or hypersensitivity to mushroom-derived products
  • Current use of supplements or medications that may influence physical performance, inflammatory status, or immune function, as determined by the investigator
  • Participation in another clinical trial within 30 days prior to enrollment
  • Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of the study results

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Tukevaa hoitoa
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Tiger Milk Mushroom (TMM)
Participants in this arm consumed Tiger Milk Mushroom (Lignosus rhinocerus) supplementation at a dosage of one capsule (300mg) twice daily for 12 weeks. Physical performance, cardiovascular endurance, inflammatory biomarkers, stress levels, and overall wellbeing were assessed at baseline, week 6, and week 12.
Ravintolisä: Tiger Milk Mushroom (TMM)
Participants received Tiger Milk Mushroom (Lignosus rhinocerus) capsules containing 300 mg of TMM extract per capsule. Participants consumed one capsule orally twice daily for 12 weeks.
Placebo Comparator: Placebo
Participants in this arm consumed matching placebo capsules at a dosage of one capsule twice daily for 12 weeks. The placebo capsules were identical in appearance to the active supplement. Physical performance, cardiovascular endurance, inflammatory biomarkers, stress levels, and overall wellbeing were assessed at baseline, week 6, and week 12.
Ravintolisä: Placebo
Participants received matching placebo capsules identical in appearance to the active supplement. Participants consumed one capsule orally twice daily for 12 weeks.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Maximal Oxygen Uptake (VO₂max)
Aikaikkuna: Baseline, Week 6, and Week 12
Change in estimated maximal oxygen uptake (VO₂max), an indicator of aerobic capacity and cardiovascular endurance. VO₂max was estimated using the Rockport One-Mile Walk Test based on walk completion time, post-exercise heart rate, age, sex, and body weight.
Baseline, Week 6, and Week 12
Change in Isometric Muscle Strength
Aikaikkuna: Baseline, Week 6, and Week 12
Muscle strength (kgf) of the elbow flexors, wrist extensors, shoulder abductors, hip flexors, knee extensors, and foot dorsiflexors was measured using a handheld muscle assessment dynamometer. Higher values indicate greater muscle strength (better outcome).
Baseline, Week 6, and Week 12
Change in Rating of Perceived Exertion (RPE)
Aikaikkuna: Baseline, Week 6, and Week 12
Rate of perceived exertion (RPE) was assessed using the Borg Category-Ratio 10 (CR10) Scale, with scores ranging from 0 to 10, where 0 indicates no exertion and 10 indicates maximal exertion. Lower scores indicate lower perceived exertion (better outcome), whereas higher scores indicate greater perceived exertion (worse outcome).
Baseline, Week 6, and Week 12

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Total Iron Binding Capacity (TIBC)
Aikaikkuna: Baseline, and Week 12
Total iron-binding capacity (TIBC) (mg/L) was measured using an enzyme-linked immunosorbent assay (ELISA). TIBC was assessed as an indicator of iron-binding capacity and oxygen transport potential. Higher values indicate greater iron-binding capacity.
Baseline, and Week 12
Change in Serum Cortisol Levels
Aikaikkuna: Baseline, Week 6, and Week 12
Salivary cortisol concentration (ng/mL) was measured using an enzyme-linked immunosorbent assay (ELISA). Lower concentrations indicate lower physiological stress (better outcome).
Baseline, Week 6, and Week 12
Change in Creatine Kinase Levels
Aikaikkuna: Baseline, and Week 12
Serum creatine kinase (CK) concentration (U/L) was measured using an enzyme-linked immunosorbent assay (ELISA). CK concentration was assessed as a biomarker of exercise-induced muscle damage. Lower CK concentrations indicate reduced muscle damage (better outcome).
Baseline, and Week 12
Changes in Lactate Levels
Aikaikkuna: Baseline and week 12
Blood lactate concentration (mg/dL) was measured using an enzyme-linked immunosorbent assay (ELISA). Lower concentrations indicate reduced metabolic fatigue and improved exercise recovery (better outcome).
Baseline and week 12
Change in Inflammatory Levels
Aikaikkuna: Baseline, and Week 12
Serum interleukin-2 (IL-2) and interleukin-6 (IL-6) concentrations (pg/mL) were measured using enzyme-linked immunosorbent assays (ELISA) to assess immune and inflammatory responses following Tiger Milk Mushroom supplementation.
Baseline, and Week 12
Change in Perceived Stress Scale (PSS-10) Score
Aikaikkuna: Baseline, Week 6, and Week 12
Perceived Stress Scale-10 (PSS-10) score. The PSS-10 consists of 10 items scored on a 5-point Likert scale (0-4), with a total score ranging from 0 to 40. Higher scores indicate greater perceived stress (worse outcome), whereas lower scores indicate lower perceived stress (better outcome).
Baseline, Week 6, and Week 12
Change in Visual Analogue Scale (VAS) Score on Physical Fitness
Aikaikkuna: Baseline, Week 6, and Week 12
Visual Analogue Scale (VAS) for Exercise Performance: Participants rated their overall perceived exercise performance using a 10-point Visual Analogue Scale (VAS). Scores range from 1 to 10, with 1 indicating the poorest perceived exercise performance and 10 indicating the best perceived exercise performance. Higher scores indicate better perceived exercise performance (better outcome).
Baseline, Week 6, and Week 12
Red Blood Cell Count
Aikaikkuna: Baseline and Week 12
Red blood cell (RBC) count (×10⁶/µL) measured using an automated hematology analyzer. RBC count was assessed to evaluate the hematological safety of Tiger Milk Mushroom supplementation.
Baseline and Week 12
White Blood Cell Count
Aikaikkuna: Baseline and Week 12
White blood cell (WBC) count (×10³/µL) measured using an automated hematology analyzer. WBC count was assessed to evaluate the hematological safety of Tiger Milk Mushroom supplementation.
Baseline and Week 12
Platelet Count
Aikaikkuna: Baseline and Week 12
Platelet count (×10³/µL) measured using an automated hematology analyzer. Platelet count was assessed to evaluate the hematological safety of Tiger Milk Mushroom supplementation.
Baseline and Week 12
Hepatic Function
Aikaikkuna: Baseline and week 12
Hepatic function was assessed by measuring serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) activities (U/L) using an automated clinical chemistry analyzer. These parameters were evaluated to assess the hepatic safety of Tiger Milk Mushroom supplementation.
Baseline and week 12
Blood Urea Nitrogen (BUN) Concentration
Aikaikkuna: Baseline and week 12
Blood urea nitrogen (BUN) concentration (mmol/L) measured using an automated clinical chemistry analyzer. BUN concentration was assessed to evaluate renal safety following Tiger Milk Mushroom supplementation.
Baseline and week 12
Serum Creatinine Concentration
Aikaikkuna: Baseline and week 12
Serum creatinine concentration (µmol/L) measured using an automated clinical chemistry analyzer. Serum creatinine concentration was assessed to evaluate renal safety following Tiger Milk Mushroom supplementation.
Baseline and week 12
Estimated Glomerular Filtration Rate (eGFR)
Aikaikkuna: Baseline and week 12
Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m²) calculated from serum creatinine using a validated equation and reported by the clinical laboratory. eGFR was assessed to evaluate renal function and the renal safety of Tiger Milk Mushroom supplementation.
Baseline and week 12

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Nexus Wise Sdn Bhd

Yhteistyökumppanit

UCSI University

Tutkijat

  • Päätutkija: Chung Keat Tan, PhD, UCSI University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 1. tammikuuta 2025

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 31. joulukuuta 2025

Opintojen valmistuminen (Todellinen)

Sunnuntai 31. toukokuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 28. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Lauantai 8. elokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 11. elokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 11. elokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Lauantai 8. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muut tutkimustunnusnumerot

  • IEC-2024-FMHS-0006

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Individual participant data underlying the results reported in publications arising from this study, after de-identification, may be made available upon reasonable request to the Principal Investigator.

IPD-jaon aikakehys

Individual participant data underlying the results reported in publications arising from this study, after de-identification, may be made available upon reasonable request to the Principal Investigator.

IPD-jaon käyttöoikeuskriteerit

Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the study investigators may gain access to the data. Requests should be directed to the Principal Investigator. Data will be shared following review and approval of the request and execution of an appropriate data sharing agreement.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF
  • CSR

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa